Watson biological was accused of selling assets cheaply. What's going on here?

Investors and managers are a pair of contradictory combinations. Because investors and managers think differently, there will be a huge gap in their responses to the same thing. In the face of interests, I'm afraid everyone thinks of themselves, not others.

In fact, there are many things that the management of listed companies hollowed out listed companies through various means. Listed companies are just a platform, and their core resources are actually limited. As long as a listed company has no core assets, it is just a worthless shell. Watson biological wanted to transfer 32.60% equity of Shanghai Zerun, and was accused? You are going to lay eggs. Kill chickens? .

First,? Kill the chickens that lay eggs? As we all know, the research and development of vaccines can not be completed in a short time. At the same time, in the process of vaccine development, it is also very expensive. So this will lead vaccine research and development companies to rely heavily on funds. The same vaccine research and development company's later income is also faster.

As long as there are successful products on the market, vaccine companies are successful. Shanghai Zerun is this one? A chicken that lays eggs? . Shanghai Zerun bivalent HPV vaccine has been reported for production, and the 9-valent HPV vaccine has also entered the clinical stage. Watson biological sold Shanghai Zerun at this time, didn't he? Kill the chickens that lay eggs? . Therefore, investors in watson biological questioned the management's practice. After all, if watson biological has problems with its own funds, it doesn't have to sell Shanghai Zerun. There are still many ways for listed companies to raise funds.

Second, it is also necessary for listed companies to sell assets at low prices. Watson biological was accused of selling assets cheaply because many investors did not recognize the valuation of Shanghai Zerun.

The target company of Shanghai Zerun is Wan Tai Bio, and the market value of Wan Tai Bio has reached more than 70 billion. On the other hand, 32.60% equity of Haizerun can only be sold at 1 1.4 1 100 million yuan. Although Wan Tai Bio has officially listed its products, its valuation is definitely much higher than that of Shanghai Zerun. However, the valuation of Shanghai Zerun is less than one twentieth of that of Wan Tai Bio, which is really too low.

Ladies and gentlemen, what do you think of watson biological's alleged sale of assets at a low price? You can speak freely in the comments section.